I CARE: Understanding skin-related immune side effects from cancer immunotherapy
Official title: Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
Funded at City College of New York · NIH-11413612 · Data updated 2026-11-12
This program studies immune-related skin side effects from cancer immunotherapy to improve how patients are counseled and cared for.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 26, 2008 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $193,496 |
| NIH project number | 5U54CA132378-18 |
| Project ID | NIH-11413612 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults undergoing cancer treatment with immune checkpoint inhibitors, especially those with or at risk for cutaneous adverse events and varied socioeconomic backgrounds.
✕Less likely to help
Patients not experiencing ircAEs or those not receiving ICIs may not benefit directly.
What this research studies
Cancer patients receiving immune checkpoint inhibitors can develop inflammatory skin problems called ircAEs, which can affect quality of life and treatment decisions. The project will examine biological and social factors that influence who is most at risk and who experiences worse outcomes, using skin tissue and other samples. By studying these skin reactions, doctors hope to tailor supportive care and possibly adjust cancer treatment for those at higher risk. The work will build on existing biological samples and data to connect biology with patient experiences across diverse populations.
Why it matters
Potential benefit: Patients could receive more personalized care to prevent or mitigate skin-related side effects and maintain cancer treatment when possible.
How similar studies have gone: Previous research has shown that identifying risk factors can lead to better management of irAEs, though more work is needed for cutaneous irAEs and diverse populations.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Vuong, Bao Q — City College of New York
- Study coordinator: Vuong, Bao Q
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.